As the FDA Begins to Address New Types of Lipid Emulsions for Parenteral Nutrition

Abstract

Get full access to this article

View all access options for this article.

References

Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed April 4, 2013.

Food and Drug Administration. Summary basis of approval and medical officer review documents for intravenous lipid emulsions. Obtained from www.foiservices.com

Troendle

Medical officer’s review and evaluation of IND amendment, March 16, 1993, designated as part of “NDA 19,531” for Nutrilipid 10% and Nutrilipid 20%. Countersigned by Solomon Sobel, Division Director, March 16, 1993. Obtained from www.foiservices.com

Food and Drug Administration. Current drug shortages: Intravenous fat emulsion. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314740.htm. Accessed April 17, 2013.

Food, Drug, and Cosmetic Act. http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/. Accessed April 4, 2013.

Vanek

Seidner

Allen

. A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27:150-192.

Code of Federal Regulations. http://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR. Accessed April 4, 2013.

A.S.P.E.N. Corporate Scientific Council. Letter to Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, December 27, 2012. https://www.nutritioncare.org/News/A_S_P_E_N__Advocating_for_New_IV_Fat_Emulsions/. Accessed May 2, 2013.